SHC016
MISSION® pLKO.1-puro 非靶 shRNA 对照质粒DNA
Targets no known genes from any species
别名:
MISSION® 对照载体, shRNA对照, 阴性shRNA对照, 阴性对照, 非靶shRNA, 非靶shRNA对照, 非靶对照
产品名称
MISSION® pLKO.1-puro 非靶 shRNA 对照质粒DNA, Targets no known genes from any species
product line
MISSION®
concentration
500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)
shipped in
dry ice
storage temp.
−20°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
MISSION® pLKO.1-puro非靶标shRNA对照质粒DNA已用作以下应用的转导对照：
- 转导肿瘤细胞用于多色成像
- 转导成人低钙诱导角质形成(HaCaT)细胞
- 转导小鼠胚胎成纤维细胞，研究IP6K1（肌醇六磷酸激酶）的生物学功能
- 研究星形胶质细胞分化中的Zac1（调节细胞凋亡和细胞周期阻滞的锌指蛋白）表达
General description
MISSION pLKO.1-puro非靶标shRNA对照质粒DNA是一种慢病毒质粒载体。载体含有不靶向任何物种任何已知基因的shRNA（小发卡状RNA）插入片段，适合在使用MISSION shRNA文库克隆的实验中用作阴性对照。可用于检测转染的小发卡RNA对基因表达的影响，并解读shRNA克隆的敲低效应。氨苄青霉素和嘌呤霉素抗生素抗性基因分别用于细菌和哺乳动物细胞的选择性筛选。此外，利用表达载体与相容包装质粒共转染包装细胞(HEK293T)，可生产自灭活复制缺陷病毒颗粒。非靶标shRNA对照质粒DNA产品为溶于Tris-EDTA(TE)缓冲液的500 ng/μl溶液，含有10 μg质粒DNA。
Legal Information
使用本产品需遵守一个或多个许可协议。有关详细信息，请参阅http://sigmaaldrich.com/missionlicense。
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
Deletion of inositol hexakisphosphate kinase 1 (IP6K1) reduces cell migration and invasion, conferring protection from aerodigestive tract carcinoma in mice
Jadav RS, et al.
Cellular Signalling, 28(8), 1124-1136 (2016)
Brain tumour cells interconnect to a functional and resistant network
Osswald M, et al.
Nature, 528(7580), 93-93 (2015)
Peroxiredoxin 2 nuclear levels are regulated by circadian clock synchronization in human keratinocytes
Avitabile D, et al.
The International Journal of Biochemistry & Cell Biology, 53(7580), 24-34 (2014)
D O Velez et al.
Nature communications, 8(1), 1651-1651 (2017-11-23)
The topographical organization of collagen within the tumor microenvironment has been implicated in modulating cancer cell migration and independently predicts progression to metastasis. Here, we show that collagen matrices with small pores and short fibers, but not Matrigel, trigger a
Sophie Weil et al.
Neuro-oncology, 19(10), 1316-1326 (2017-04-19)
Primary and adaptive resistance against chemo- and radiotherapy and local recurrence after surgery limit the benefits from these standard treatments in glioma patients. Recently we found that glioma cells can extend ultra-long membrane protrusions, "tumor microtubes" (TMs), for brain invasion
相关内容
Instructions
SHC016 Vector Map
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持